A carregar...
Treating acquired resistance to EGFR-tyrosine kinase inhibitors:still a work in progress
While most patients with metastatic non-small cell lung cancer (NSCLC) containing sensitizing mutations in the epidermal growth factor receptor (EGFR) gene will achieve an objective response to EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, patients inevitably develop resista...
Na minha lista:
| Publicado no: | Transl Lung Cancer Res |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Pioneer Bioscience Publishing Company
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4367570/ https://ncbi.nlm.nih.gov/pubmed/25806172 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2012.05.01 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|